Related Experiment Videos
High-intensity chemotherapy with peripheral blood progenitor cell support
D Fennelly1, L Vahdat, J Schneider
1Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY.
Seminars in Oncology
|April 1, 1994
Summary
This study shows that high-dose chemotherapy with hematopoietic stem cell rescue is feasible, enabling shorter treatment intervals. This approach advances cancer therapy for breast and ovarian cancers.
Area of Science:
- Oncology
- Hematology
- Cancer Therapy
Background:
- High-dose chemotherapy requires effective stem cell rescue to mitigate toxicity.
- Hematopoietic growth factors and peripheral blood progenitor cells offer a viable rescue strategy.
Purpose of the Study:
- To assess the feasibility of delivering multiple high-dose chemotherapy courses at abbreviated intervals.
- To evaluate novel cross-over regimens supported by hematopoietic growth factors and peripheral blood progenitor cell rescue.
Main Methods:
- Clinical studies utilizing cyclophosphamide induction chemotherapy followed by granulocyte colony-stimulating factor.
- Peripheral blood leukapheresis for progenitor cell harvesting and subsequent rescue.
- Administration of various high-dose consolidation regimens including carboplatin, etoposide, cyclophosphamide, and thiotepa.
Main Results:
- Demonstrated feasibility of cross-over regimens with abbreviated treatment intervals (median ~16 days).
- Successful rescue using autologous peripheral blood progenitor cells after multiple high-dose chemotherapy courses.
- Established the safety and tolerability of high-intensity, dose-dense chemotherapy regimens.
Conclusions:
- High-intensity, dose-dense chemotherapy regimens are feasible with hematopoietic progenitor cell support.
- This approach facilitates abbreviated treatment intervals, potentially improving patient outcomes.
- Current research aims to develop disease-specific regimens for breast and ovarian cancers based on these findings.